Vaxcyte, Inc. PCVX Business Segments — Operating Expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s business segments — operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vaxcyte, Inc.'s business segments — operating expenses?
- Vaxcyte, Inc. (PCVX) reported business segments — operating expenses of $345.85M in Q1 2026.
- How has Vaxcyte, Inc.'s business segments — operating expenses changed year-over-year?
- Vaxcyte, Inc.'s business segments — operating expenses increased by 91.3% year-over-year, from $180.79M to $345.85M.
- What is the long-term trend for Vaxcyte, Inc.'s business segments — operating expenses?
- Over 3 years (2022 to 2025), Vaxcyte, Inc.'s business segments — operating expenses has grown at a 58.4% compound annual growth rate (CAGR), from $232.26M to $923.68M.
- What does business segments — operating expenses mean?
- This metric aggregates all costs directly related to the operational activities of the business segment, including research, development, and administrative overhead. It provides a comprehensive view of the total capital required to maintain the segment's current business model and development programs. Investors use this to evaluate the overall burn rate and operational intensity of the segment.